ABC | Volume 113, Nº2, August 2019

Short Editorial Arq Bras Cardiol. 2019; 113(2):258-259 Sarabanda Costs reduction after AF ablation in Brazil 1. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-444. 2. Kim M, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313-20. 3. Colilla S, Crow A, PetkunW, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112(8):1142-7. 4. Marcolino MS, Palhares DM, Benjamin EJ, Ribeiro AL. Atrial fibrillation: prevalence in a large database of primary care patients in Brazil. Europace. 2015;17(12):1787-90. 5. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639-54. 6. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-66. 7. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261-74. 8. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1275-85. 9. Marrouche NF, Brachmann J, Andresen D, Vogt J, Siebels J, Boersma L, et al. Catheter ablation for atrial fibrillation with left ventricular dysfunction. N Engl J Med. 2018;378(5):417-27. 10. Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M, et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes. 2012;5(2):171-81. 11. Saad EB, Tayar DO, Ribeiro RA, Junqueira Jr. SM, Andrade P, d’Avila A. Redução na Utilização de Recursos em Saúde e dos Custos após Ablação por Radiofrequência da Fibrilação Atrial no Brasil. Arq Bras Cardiol. 2019; 113(2):252-257 12. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009;2(4):362-69. 13. Ladapo JA, David G, Gunnarsson CL, Hao SC, White SA, March JL, et al. Healthcare utilization and expenditures in patients with atrial fibrillation treated with cateter ablation. J Cardiovasc Electrophysiol. 2012;23(1):1–8. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 259